MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ibneur.2026.02.019

Медицинская библиотека · IBRO neuroscience reports · 2026

A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease.

Lehmann Hillel, Azmanov Henny, Hershkovitz Yoav, Hurvitz Noa, Agus Samuel, Berg Marc, Arkadir David, Ilan Yaron

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Parkinson's disease (PD) is a neurodegenerative disorder treated with Levodopa, but long-term use often causes motor complications like "wearing-off," "on-off" effects, and Levodopa-induced dyskinesias, requiring careful management to balance benefits and risks. The Constrained Disorder Principle (CDP) defines biological systems by their inherent variability. CDP-based second-generation artificial intelligence (AI) systems introduce controlled variability into treatment regimens to counteract compensatory mechanisms that underlie drug loss of effectiveness.

OBJECTIVES

This open-label, proof-of-concept feasibility clinical trial aimed to assess the technical feasibility and preliminary evidence of improved response to Levodopa by implementing algorithm-controlled therapeutic regimens.

METHODS

In this 14-week, open-label, single-center study, five PD patients used an app that randomized their Levodopa dosing times and dosages within pre-defined ranges. Primary outcomes were changes in the Unified Parkinson's Disease Rating Scale (UPDRS) and the Patient Global Impression of Improvement (PGI-I) scale. Statistical analysis was performed using the Wilcoxon signed-rank test with effect size calculations.

RESULTS

80% of patients demonstrated clinical improvement on the UPDRS, with a mean improvement of 4.4 points (p = 0.063, Cohen's d=0.82, 95% CI: -0.3-9.1), approaching but not exceeding the established minimal clinically significant difference threshold. Additionally, 60% reported a subjective improvement on the PGI-I scale. Furthermore, 80% of patients used the app daily, indicating high adherence.

CONCLUSIONS

The results of this feasibility trial provide preliminary, hypothesis-generating evidence that CDP-based second-generation AI-driven personalized Levodopa dosing regimens may be technically feasible and potentially associated with clinical improvements in PD patients. However, the open-label design, small sample size, and absence of control conditions necessitate cautious interpretation. Adequately powered, randomized, double-masked controlled trials are needed to confirm these findings and rigorously evaluate efficacy and long-term effects.

Для цитирования: Lehmann Hillel, Azmanov Henny, Hershkovitz Yoav, Hurvitz Noa, Agus Samuel, Berg Marc, Arkadir David, Ilan Yaron. A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease.. IBRO neuroscience reports. 2026. DOI: 10.1016/j.ibneur.2026.02.019.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.